To order this detailed 780+ page report, please visit this link
Key Inclusions
§ A detailed review ofthe overall landscape of the biopharmaceutical contract manufacturing market,featuring an elaborate list of active CMOs, along with information on a numberof relevant parameters, such as year of establishment, company size, location ofheadquarters, types of biologics manufactured (peptides / proteins, antibodies,vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors,biosimilars, nucleic acids and others), scale of operation (preclinical,clinical and commercial), types of expression systems used (mammalian,microbial and others), type of bioreactor used (single-use bioreactors andstainless steel bioreactors), mode of operation of bioreactors (batch,fed-batch and perfusion), bioprocessing capacity and type of packaging.
§ A detailed landscapeof the biopharmaceutical manufacturing facilities established across the keygeographical regions (North America, Europe, Asia-Pacific and Rest of theWorld), and including an analysis based on the location of these facilities,highlighting key manufacturing hubs for biologics.
§ Elaborate profiles ofkey players that claim to have a diverse range of capabilities related to thedevelopment, manufacturing and packaging of biologics. Each profile provides anoverview of the company, its financial performance (if available), informationrelated to its service portfolio, manufacturing facilities, and details onpartnerships, recent developments (expansions), as well as an informed futureoutlook.
§ A detailed discussionon the key enablers in this domain, including certain niche product classes,such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies,gene therapies and viral vectors, which are likely to have a significant impacton the growth of the contract services market.
§ A case study on thegrowing global biosimilars market, highlighting the associated opportunitiesfor biopharmaceutical CMOs and CDMOs.
§ A case studycomparing the key characteristics of small and large molecule drugs, along withdetails on the various steps involved in their respective manufacturingprocesses.
§ A detailed discussionon the benefits and challenges associated with in-house manufacturing,featuring a brief overview of the various parameters that a drug / therapydeveloper may need to take into consideration while deciding whether tomanufacture its products in-house or outsource the production operations.
§ A qualitativeanalysis, highlighting the various factors that need to be taken intoconsideration by biopharmaceutical therapeutics / drug developers whiledeciding whether to manufacture their respective products in-house or engagethe services of a CMO.
§ A review of thevarious biopharmaceutical based manufacturing initiatives undertaken by bigpharma players (shortlisted on the basis of the revenues generated by the top10 pharmaceutical companies in 2019), highlighting trends across variousparameters, such as number of initiatives, year of initiative, purpose ofinitiative, type of initiative, scale of operation, types of biologicsmanufactured and type of product.
§ An analysis of therecent developments within the biopharmaceutical contract manufacturingindustry, highlighting information on the funding and technology advancementsrelated to biomanufacturing.
§ A detailed capacityanalysis, taking into consideration the individual development andmanufacturing capacities of various stakeholders (small, mid-sized, large andvery large CMOs / CDMOs) engaged in the market, using data from both secondaryand primary research. The study examines the distribution of globalbiopharmaceutical manufacturing capacity by scale of operation (preclinical /clinical, commercial), company size (small, mid-sized, large and very large),and geography (North America (the US and Canada), Europe (Italy, Germany,France, Spain, the UK and rest of Europe), Asia-Pacific (China, India, Japan,South Korea and Australia), Latin America, Middle East and North Africa).
§ API
§ FDF
§ Typesof Expression Systems Used
§ Mammalian
§ Microbial
§ Others
§ Scaleof Operation
§ Preclinical/ Clinical
§ Commercial
§ CompanySize
§ Small
§ Mid-sized
§ Large/ Very Large
§ Typesof Biologics Manufactured
§ AntibodyTherapeutics
§ Vaccines
§ CellTherapies
§ OtherBiologics
§ KeyGeographical Regions
§ NorthAmerica
§ Europe
§ Asia-Pacific
§ LatinAmerica
§ MiddleEast and North Africa
To request sample pages, please visit this link
Key Questions Answered
§ Whoare the leading players engaged in offering contract manufacturing services forbiologics?
§ What percentage of the biopharmaceutical manufacturingoperations are presently outsourced?
§ What factors should be taken into consideration whiledeciding whether the manufacturing operations for biologics should be keptin-house or outsourced?
§ What is the current, installed capacity for contractmanufacturing of biopharmaceuticals?
§ What is the current, global demand for biologics? How isthe demand for such candidates likely to evolve in the foreseen future?
§ Which regions are the key manufacturing hubs for biologics?
§ What type of partnership models are commonly adopted bystakeholders engaged in this domain?
§ What are the different biopharmaceutical focusedinitiatives undertaken by big pharma players in the recent past?
§ How is the current and future market opportunity likely tobe distributed across key market segments?
You may also be interested in the following titles:
1. Vaccine Contract Manufacturing Market(3rd Edition), 2021-2030
2. ADC Contract Manufacturing Market (4thEdition), 2020-2030
3. Microbial Contract Manufacturing Market,2020-2030
Contact Information
GauravChaudhary
+1(415) 800 3415
gaurav.chaudhary@rootsanalysis.com
Facebook- https://www.facebook.com/RootsAnalysis
LinkedIn- https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter- https://twitter.com/RootsAnalysis
